Leber Hereditary Optic Neuropathy (LHON) Historical Case Record Survey

计划入组 306 人 · 首次发布于 2013 年 7 月 8 日

Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients

计划入组 19 人 · 首次发布于 2014 年 2 月 17 日

Trial of Cyclosporine in the Acute Phase of Leber Hereditary Optic Neuropathy

计划入组 12 人 · 首次发布于 2014 年 6 月 27 日

AAV2 smCBA based ND4 gene therapy (Leber hereditary optic neuropathy)

Idebenone(Raxone)

C₁₉H₃₀O₅ · Rx

RNA actuator therapeutic for hereditary angioedema(CAMP4 Therapeutics)

Brian Leber

United States

Orthocell Ltd

Ocugen

United States

GenSight Biologics Successfully Transfers LUMEVOQ Manufacturing to Catalent for LHON Gene Therapy

LUMEVOQ Gene Therapy Shows Sustained Vision Improvement in LHON Patients After 5 Years

GenSight's Gene Therapy Shows Better Outcomes When Administered During Dynamic Phase of LHON Disease